Inventor · disambiguated record
Guowei Song
Also filed as: SONG GUOWEI
3 granted patents·6 pending applications·9 citations·filing 2017–2024
66Inventor score
Files withRISEN SUZHOU PHARMA TECH CO LTD5SUZHOU ARK BIOPHARMACEUTICAL CO LTD2INNOVENT BIOLOGICS SUZHOU CO LTD1ZHEJIANG VIMGREEN PHARMACEUTICALS LTD1
Top patents by PatentIndex Score
9 records- 0189US10954188B2Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereofRISEN SUZHOU PHARMA TECH CO LTD·Filed 2019·Granted Mar 23, 2021·4 cites·17 claims
- 0285US12459888B2Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereofRISEN SUZHOU PHARMA TECH CO LTD·Filed 2024·Granted Nov 4, 2025·0 cites·3 claims
- 0385US10472323B2Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereofRISEN SUZHOU PHARMA TECH CO LTD·Filed 2017·Granted Nov 12, 2019·5 cites·20 claims
- 0477US2023295079A1Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereofRISEN SUZHOU PHARMA TECH CO LTD·Filed 2022·Application pending·0 cites
- 0569US2021347731A1Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereofRISEN SUZHOU PHARMA TECH CO LTD·Filed 2021·Application pending·0 cites
- 0655US2025144220A1Conjugate for preventing and treating viral infections and use thereofSUZHOU ARK BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0749US2025026742A1Compound as atr kinase inhibitorSUZHOU ARK BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0843US2023257374A1Novel kras g12c protein inhibitor, preparation method therefor, and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 0942US2023048888A1Use of triazolotriazine derivative in treatment of diseasesZHEJIANG VIMGREEN PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Guowei Song files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →